- Report
- November 2021
- 1032 Pages
Global
From €4772EUR$5,000USD£3,998GBP
The Prostate Cancer Biomarker market is a subset of the larger Biomarker market, which is focused on the development and use of biomarkers to diagnose, monitor, and treat diseases. Prostate cancer biomarkers are used to detect the presence of prostate cancer, as well as to monitor the progression of the disease. These biomarkers can be used to identify patients who are at risk of developing prostate cancer, as well as those who are likely to respond to treatment.
The Prostate Cancer Biomarker market is highly competitive, with a number of companies offering products and services. These include companies such as Genomic Health, Myriad Genetics, and Exact Sciences, which offer diagnostic tests for prostate cancer. Other companies, such as Illumina and Thermo Fisher Scientific, provide products and services for the development and use of biomarkers. Additionally, there are a number of companies that specialize in the development of novel biomarkers for prostate cancer. Show Less Read more